CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.
News|Articles|October 15, 2026
Alvotech files first known aflibercept 8 mg biosimilar with EMA
Author(s)Kassi Filkins
AVT29, filed as a line extension to Mynzepli, reaches EMA before its phase 3 comparative trial in DME reads out in mid-2027.
Advertisement
Advertisement
Alvotech and Advanz Pharma have submitted a European regulatory application for AVT29, a proposed biosimilar to high-dose aflibercept 8 mg (Eylea 8 mg; Bayer/Regeneron), already marketed as Eylea HD in the United States.1 The companies describe it as the first regulatory submission worldwide for a biosimilar to the 8 mg formulation.1
Related to this article
The FDA approved Lucamzi (ranibizumab-blrz), Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.
The epidemiology, inflammatory pathophysiology, diagnosis, and treatment of diabetic macular edema are discussed during Inflammatory Eye Disease Week.
October spotlights eye-care breakthroughs: phase 3 gene therapies, sustained delivery, and AAO trial data, plus 3 FDA clearances shaping retina, cataract, and TED care.
Now on the company's EYE7 smart glasses platform, Eva is designed to go beyond answering questions about the visual environment by reasoning about user needs and directly controlling the device's vision-enhancement features.
An estimated 9.6 million people in the US have diabetic retinopathy, and roughly 1 in 3 patients with diabetes miss annual eye exams as AI screening and new therapies reshape care.
The FDA approved the Supplemental New Drug Application for phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) to treat presbyopia.
Eye care providers urged FDA advisers to approve SYD-101, citing myopia’s lifelong risks, compounding gaps and STAR trial results.
Advertisement
Advertisement